Linc01638 promotes tumorigenesis in HER2+ breast cancer.

In this study, linc01638 was found to be remarkably overexpressed in HER2-positive breast cancer cells and tissues. Suppression of linc01638 enhanced cell apoptosis, as well as inhibited the growth and invasiveness of HER2-positive breast cancer cells in vitro and tumor progression and metastasis in vivo. Furthermore, inhibition of linc01638 by shRNA attenuated expression of DNMT1, DNMT3a, and DNMT3b,and promoted expression of BRCA1 and PTEN in HER2-positive breast cancer cells and mouse xenograft models, indicating that linc01638 promoted tumorigenesis, partly by stimulating DNMTs signaling pathway and inhibiting expression of BRCA1/PTEN in HER2-positive breast cancer. These findings collectively suggest that linc01638 might be a promising biomarker and therapeutic target for treatment of HER2-positive breast cancer.
PMID: 29992881 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - July 9, 2018 Category: Cancer & Oncology Authors: Liu P, Tang H, Wu J, Qiu X, Kong Y, Zhang L, Xie X, Xiao X Tags: Curr Cancer Drug Targets Source Type: research